Navigation Links
Device That Targets Brain Cancer Shows Promising Results

Early data for an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields , called Tumor-Treating Fields (TTFields), has found that it more than doubled the median overall survival rates in patients with the most common and aggressive type of malignant brain tumor.

The device, called the Novo-TTF, uses electrical fields to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off instead of dividing and growing.

Healthy brain cells rarely divide and have different electrical properties than cancerous brain cells. This allows the device to target cancer cells without affecting the healthy cells.

The 10 patients who were being treated with the device were suffering from recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.

Researchers found that among the patients treated with the Novo-TTF, the median length of time to disease progression was 26.1 weeks; progression free survival at six months was 50 percent; and median overall survival was 62.2 weeks.

This is more than double the rates reported in historical data approximately 9.5 weeks, 15.3 percent, and 29.3 weeks, respectively.

"The novel mechanism of action of the Novo-TTF relies on the physical properties of the cancer cells, their shape and size, rather than the chemical make-up. We believe that this distinction enables the device to stop local proliferation and metastasis of cancer, which would explain the efficacy observed in these early findings," said Dr. Elion Kirson lead author and Vice President of Research and Development, NovoCure.

"Based on our preliminary research, we believe that there is a high probability that TTFields may prove to be an effective and safe approach to treating a large number of human cancers," Dr Kirson a dded.

This research, which includes the results of cell culture, animal and early phase human trials, appears in the current issue of the Proceedings of the National Academy of Sciences (PNAS).


'"/>




Related medicine news :

1. Injection supports Heart Devices
2. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
3. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. New Implantable Device That Can Keep The Heart Ticking
6. Making MRIs Safe for Patients With Implantable Heart Devices
7. Researchers Develop Device For Detecting Atherosclerotic Plaques
8. A Cheap Device to Stop Snoring from New Zealand
9. Scientists Concerned Over Increasing Malfunction Of Heart Devices
10. Device For Improving Bone Mass In Osteoporosis
11. Anti-Microbial Coating For Use Over Biomedical Devices Developed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology: